Literature DB >> 3546183

Activity of flavone acetic acid (NSC-347512) against solid tumors of mice.

T H Corbett, M C Bissery, A Wozniak, J Plowman, L Polin, E Tapazoglou, J Dieckman, F Valeriote.   

Abstract

Flavone acetic acid (FAA) is a new antitumor agent that has recently entered Phase I clinical trials. In preclinical studies, we have found that FAA was broadly active against a variety of transplantable solid tumors of mice (colon #51, #07, #10, #26; pancreatic ductal adenocarcinomas #02 and #03; mammary adenocarcinoma #16/C/Adr; M5076 reticulum cell sarcoma and Glasgow's osteosarcoma). FAA was curative for colon adenocarcinoma #10 and pancreatic ductal adenocarcinoma #03. Thus, for the first time an agent has been identified with very broad, perhaps nearly universal solid tumor activity. FAA was also found to be orally active and stable in solution at 37 degrees C for 48 h. FAA was selectively cytotoxic in vitro for solid tumors over leukemias L1210 and P388 (in a soft-agar colony formation assay), thus correlating cellular selectivity in vitro with in vivo antitumor activity. The finding that FAA was active in vitro, established that the agent did not need metabolism (activation) outside the tumor cell. The main drawback of FAA was an unusual 'threshold' behavior in which only a narrow range of doses were active and splitting the dose markedly decreased activity.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3546183     DOI: 10.1007/BF00179586

Source DB:  PubMed          Journal:  Invest New Drugs        ISSN: 0167-6997            Impact factor:   3.850


  20 in total

1.  Tumor induction relationships in development of transplantable cancers of the colon in mice for chemotherapy assays, with a note on carcinogen structure.

Authors:  T H Corbett; D P Griswold; B J Roberts; J C Peckham; F M Schabel
Journal:  Cancer Res       Date:  1975-09       Impact factor: 12.701

Review 2.  Current NCI preclinical antitumor screening in vivo: results of tumor panel screening, 1976-1982, and future directions.

Authors:  J M Venditti; R A Wesley; J Plowman
Journal:  Adv Pharmacol Chemother       Date:  1984

3.  Pharmacologic studies of anticancer drugs with the human tumor stem cell assay.

Authors:  D S Alberts; S E Salmon; H S Chen; T E Moon; L Young; E A Surwit
Journal:  Cancer Chemother Pharmacol       Date:  1981       Impact factor: 3.333

4.  Induction and chemotherapeutic response of two transplantable ductal adenocarcinomas of the pancreas in C57BL/6 mice.

Authors:  T H Corbett; B J Roberts; W R Leopold; J C Peckham; L J Wilkoff; D P Griswold; F M Schabel
Journal:  Cancer Res       Date:  1984-02       Impact factor: 12.701

5.  Clinical predictivity of transplantable tumor systems in the selection of new drugs for solid tumors: rationale for a three-stage strategy.

Authors:  M J Staquet; D P Byar; S B Green; M Rozencweig
Journal:  Cancer Treat Rep       Date:  1983-09

6.  Application of in vitro soft agar techniques for growth of tumor cells to the study of colon cancer.

Authors:  R N Buick; S E Fry; S E Salmon
Journal:  Cancer       Date:  1980-03-15       Impact factor: 6.860

7.  Prospective clinical trial of a human tumor cloning system.

Authors:  D D Von Hoff; G M Clark; B J Stogdill; M F Sarosdy; M T O'Brien; J T Casper; D E Mattox; C P Page; A B Cruz; J F Sandbach
Journal:  Cancer Res       Date:  1983-04       Impact factor: 12.701

8.  Metastatic behavior of a murine reticulum cell sarcoma exhibiting organ-specific growth.

Authors:  I R Hart; J E Talmadge; I J Fidler
Journal:  Cancer Res       Date:  1981-04       Impact factor: 12.701

9.  Cellular quantitation of in vivo effects of 1-beta-D-arabinofuranosylcytosine on leukemia L1210.

Authors:  M Edelstein; F Valeriote; T Vietti
Journal:  J Natl Cancer Inst       Date:  1977-04       Impact factor: 13.506

10.  Biology and therapeutic response of a mouse mammary adenocarcinoma (16/C) and its potential as a model for surgical adjuvant chemotherapy.

Authors:  T H Corbett; D P Griswold; B J Roberts; J C Peckham; F M Schabel
Journal:  Cancer Treat Rep       Date:  1978-10
View more
  40 in total

1.  Activity of batracylin (NSC-320846) against solid tumors of mice.

Authors:  P Mucci-LoRusso; L Polin; M C Bissery; F Valeriote; J Plowman; G D Luk; T H Corbett
Journal:  Invest New Drugs       Date:  1989-11       Impact factor: 3.850

2.  Flavone acetic acid antitumour activity against a mouse pancreatic adenocarcinoma is mediated by natural killer cells.

Authors:  G Damia; G Tagliabue; P Allavena; M D'Incalci
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

3.  Editorial: One small molecule: a new way to treat the flu?

Authors:  Howard Young
Journal:  J Leukoc Biol       Date:  2011-03       Impact factor: 4.962

4.  Comparative efficacy of DMP 840 against mouse and human solid tumor models.

Authors:  P LoRusso; L Demchik; M Dan; L Polin; J L Gross; T H Corbett
Journal:  Invest New Drugs       Date:  1995       Impact factor: 3.850

5.  Inhibition of antibacterial activity of himastatin, a new antitumor antibiotic from Streptomyces hygroscopicus, by fatty acid sodium salts.

Authors:  S W Mamber; K W Brookshire; B J Dean; R A Firestone; J E Leet; J A Matson; S Forenza
Journal:  Antimicrob Agents Chemother       Date:  1994-11       Impact factor: 5.191

6.  Phase I and pharmacology study of flavone acetic acid administered two or three times weekly without alkalinization.

Authors:  M de Forni; G G Chabot; J P Armand; A Gouyette; M Klink-Alak; G Recondo
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

7.  The comparative disposition of the pyrolloquinone GR63178A and its 9-hydroxy metabolite GR54374X in sensitive and resistant mouse colon adenocarcinoma.

Authors:  R C French; J Cummings; A MacLellan; J S MacPherson; A A Ritchie; J F Smyth
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

Review 8.  Flavone 8-acetic acid: our current understanding of its mechanism of action in solid tumours.

Authors:  J Cummings; J F Smyth
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

Review 9.  5-Fluorouracil containing combinations in murine tumor systems.

Authors:  T H Corbett; M C Bissery; P Mucci-LoRusso; L Polin
Journal:  Invest New Drugs       Date:  1989-04       Impact factor: 3.850

10.  Relative cardiotoxicity and cytotoxicity of anthraquinonyl glucosaminosides.

Authors:  J W Banning; H N Abramson; H C Wormser; J D Wu; T H Corbett
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.